
SUTRO BIOPHARMA, INC. STRO
SUTRO BIOPHARMA, INC. statistics & valuation
Net margin-186.5%
Return on capital-160.5%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Net margin (%)Gross margin (%)Operating margin (%)Return on equity (%)Shares outstandingNet debt ($)Share buybacks ($)Return on assets (%)Free cash flow margin (%)Debt / equity (×)EPS ($) Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|
| Operating margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | -129.8% | -96.9% | -37.2% |
| Net margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | -278.9% | -91.9% | -38.1% |
| FCF margin | — | — | — | — | — | — | — | 29.0% | -78.1% |
| Return on assets | -109.9% | -58.7% | -22.7% | -29.3% | -30.9% | -8.2% | -76.2% | -15.8% | -48.3% |
| Return on equity | 144.3% | -510.0% | -71.4% | -54.9% | -41.8% | -9.7% | -121.9% | -26.8% | 18.1% |
| Debt / equity | — | — | 0.03× | 0.07× | 0.10× | 0.07× | 0.09× | 0.11× | — |
| Current ratio | 2.01 | 2.60 | 4.50 | 5.31 | 5.24 | 12.78 | 3.90 | 5.76 | 0.80 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.